Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for ���������������,���������������������������������������:kn39��� returned no results
Showing 91 to 105 of 809 results for ���������������,���������������������������������������:know���

  1. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    retropubic mesh sling than after the other operations. It is not possible to know for sure what will happen to any individual woman 4...

  2. NICE impact cardiovascular disease management

    Find out about the progress made by the health and care system in implementing NICE guidance on cardiovascular disease management

  3. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  4. Person-centred future planning

    A quick guide for practitioners supporting people growing older with learning disabilities.

  5. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

  6. Join the public involvement programme expert panel

    Join Nice's Public Involvement Programme expert panel

  7. Moving between hospital and home, including care homes

    NICE quick guide - moving between hospital and home, including care homes

  8. Vitamin D: supplement use in specific population groups (PH56)

    This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.

  9. Notify a procedure

    Tell us about an interventional procedure you think should be assessed by NICE.

  10. Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks

    information about the options. They cover the things most women may want to know about. On page 10 you can write down how you feel about...

  11. Colorectal cancer . Patient decision aid on Lynch syndrome: should I take aspirin to reduce my chance of getting bowel cancer?

    do to reduce your risk of bowel and other cancers. It is not possible to know in advance what will happen to any one person. c NICE...

  12. Urinary tract infection (recurrent). Patient decision aid on reducing the chance of recurrent urinary tract infection (UTI) in postmenopausal women

    your GP for a review within 12 months, or an earlier agreed time. If you know that something triggers a UTI you could take an antibiotic...

  13. Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

    Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.

  14. Unintentional injuries: prevention strategies for under 15s (PH29)

    This guideline covers strategies, regulation, enforcement, surveillance and workforce development in relation to preventing unintentional injuries in the home, on the road and during outdoor play and leisure.

  15. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.